NGM Biopharmaceuticals's market cap is currently ―. The company's EPS TTM is $-1.727; its P/E ratio is -0.92; NGM Biopharmaceuticals is scheduled to report earnings on May 2, 2024, and the estimated EPS forecast is $-0.35. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	$ 582.00K	$ 1.42M	$ 2.20M	$ 18.15M	$ 7.91M
Gross Profit	$ 582.00K	$ 1.42M	$ 2.20M	$ 18.15M	-
EBIT	$ -28.80M	$ -38.26M	$ -47.69M	$ -38.50M	$ -48.30M
EBITDA	$ -29.15M	$ -38.70M	$ -48.11M	$ -38.25M	$ -47.71M
Net Income Common Stockholders	$ -28.80M	$ -38.26M	$ -47.69M	$ -36.47M	$ -47.26M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 166.04M	$ 195.04M	$ 232.50M	$ 271.49M	$ 300.15M
Total Assets	$ 192.15M	$ 219.81M	$ 258.84M	$ 307.40M	$ 335.87M
Total Debt	$ 1.38M	$ 2.75M	$ 4.07M	$ 5.38M	$ 6.69M
Net Debt	$ -164.66M	$ -192.29M	$ -228.43M	$ -266.11M	$ -293.46M
Total Liabilities	$ 22.34M	$ 28.42M	$ 37.90M	$ 307.44M	$ 49.98M
Stockholders Equity	$ 169.81M	$ 192.12M	$ 220.93M	$ 259.59M	$ 285.89M
Cash Flow	-
Free Cash Flow	$ -27.49M	$ -40.32M	$ -42.50M	$ -30.86M	$ -28.46M
Operating Cash Flow	$ -27.20M	$ -40.22M	$ -41.83M	$ -30.42M	$ -28.15M
Investing Cash Flow	$ 26.87M	$ 24.59M	$ 35.64M	$ 1.69M	$ 35.45M
Financing Cash Flow	-	$ 1.39M	$ 279.00K	$ 723.00K	$ 33.22M

Currency in USD

NGM Biopharmaceuticals Earnings and Revenue History

Income Statement >

NGM Biopharmaceuticals Debt to Assets

Balance Sheet >

NGM Biopharmaceuticals Cash Flow

Cash Flow >

NGM Biopharmaceuticals Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing